INTRODUCTION L
U N G C A N C ER is the leading cause of cancer death-the estimated incidence and mortality in the United States are 171,600 cases and 158,900 deaths in 1999, respectively (Landis et al., 1999) . Approximately 20 to 25% of patients have retherapy have not significantly improved the survival time of patients with inoperable disease. The overall 5-year survival for patients with inoperable non-small cell lung cancer (NSCLC) is about 5 to 10% (Elias, 1993; Jett, 1993; Nesbitt et al., 1995) . Approximately 75% of patients will relapse with metastases and 50 to 75% will experience disease recurrence in the chest (Elias, 1993) . The lack of successful therapeutic regimens led us to examine a novel therapeutic approach using genetically engineered viruses.
Advances in virology and molecular biology spurred the engineering of recombinan t viruses with specific properties, creating new interest in virus-based therapy of solid tum ors. One such group of viruses is the replication-selective herpes simplex virus type 1 (HSV-1) mutants Coukos et al., 1999b; Kirn, 1999) . These mutants have been engineered by deleting or mutating genes that govern viral replication or neurovirule nce. They can cause lytic infection with subsequent cell death in rapidly dividing cells but not in stationary cells. The mutants harboring deletions or mutations in the thymidine kinase (TK) gene (UL23) (Sanders et al., 1982; Martuza et al., 1991; Boviatsis et al., 1994b; Jia et al., 1994) , the ICP6 gene (UL39) encoding the large subunit of ribonucleot ide reductase (RR) (Boviatsis et al., 1994b; Mineta et al., 1995; Yazaki et al., 1995; Kramm et al., 1997) , or both copies of the g 34.5 gene (Chambers et al., 1995; Kesari et al., 1995; Randazzo et al., 1995; Andreansky et al., 1997) have dem onstrated efficacy in tumors in the CNS, including malignant gliom a, malignant meningiom a, and metastatic melanoma. ICP34.5, encoded by the g 34.5 gene, can prevent prem ature host cellular protein shutoff in the infected host through inhibition of the phosphoryla tion of the eukaryotic translation initiation factor eIF-2a (Cassady et al., 1998a) , as well as viral exit from the cell (Brown et al., 1994) . ICP34.5 is also responsible for neurovirule nce Valyi-N agy et al., 1994) . Although the neurovirule nce of the wild-type (wt) HSV-1 strain 171 is approxim ately 500-fold greater in mice than wt HSV-1 strain F (Dix et al., 1983; Valyi-Na gy et al., 1994; Kucharczuk et al., 1997) , ICP34.5-deleted mutants of both strains have exhibited 10 5 -to 10 6 -fold attenuation in neurovirule nce and can replicate more efficiently in rapidly dividing com pared with quiescent cells (MacLean et al., 1991; Chou and Roizm an, 1994; Valyi-Nagy et al., 1994) . Because of their specificity for rapidly dividing cells, cytolytic effect, and lack of neurovirule nce, ICP34.5 mutants were also investigate d in non-CNS tum ors (Coukos et al., 1999c) . They have shown efficacy in the treatm ent of intraperiton eal malignant mesothelio ma (Kucharczuk et al., 1997) , epithelial ovarian cancer (Coukos et al., 1999a) , and subcutaneou s malignant melanoma , reducing tum or size and/or prolonging survival in a dose-dependent manner. HSV-G207, which is an ICP34.5 mutant of the F strain with an insertion of Escherichia coli lacZ gene in the ICP6 gene, also demonstrat ed efficacy in the treatm ent of breast and colon cancer both in vitro and in vivo (Toda et al., 1998a,b) as well as CNS tum ors (Mineta et al., 1995; Yazaki et al., 1995) . Furthermore, the side effect profiles in the dose escalation phase I clinical trials using the ICP34.5 deletion mutant HSV-1716, or the ICP34.5-and RR-deleted HSV-1 mutant G207, for treatment of malignant gliom a have been minim al (Brow n et al., 1998; Markert et al., 1999) and thus, both HSV-1716 and HSV-G207 are prom ising therapeutic agents for cancer therapy.
Since lung tissue expressed high mRNA concentrations of herpes virus entry mediator (HVEM) (Montgomery et al., 1996) , we investigated the efficacy of HSV-1716 in vitro and in vivo against human NSCLC cell lines (Abbas et al., 1998) . We have shown that HSV-1716 is efficacious, but com plete destruction of the tumor mass has not been accom plished with viral treatm ent alone in our lung cancer xenograft models. Therefore, strategies to augment the efficacy of this treatment are being investigated. Several methods have been reported to enhance the HSV-based oncolytic effect. For example, the oncolytic effect of HSV-R3616, lacking both copies of the ICP34.5 gene, was augm ented by ionizing radiation (Advani et al., 1998) or by coexpression of interleukin 4 (IL-4) (Andreansky et al., 1998) in the treatment of malignant glioma. In addition, administration of an HSV-based amplicon expressing IL-12 increased the oncolytic effect of HSV-G207 in an experimental colon cancer model (Toda et al., 1998a) . As preliminary data, an HSV amplicon vector carrying IL-2 showed therapeutic efficacy in treating intraperitoneal metastatic gastric carcinoma in nude mice and increased killing activity of splenocytes (Tsuburaya et al., 1998) . Coadministratio n of HSV amplicon vectors expressing the chemokine RANTES and the T cell-costim ulatory ligand B7.1 also resulted in approximately 85% reduction of subcutaneous murine lym phoma nodules (Kutubuddin et al., 1998) . We have developed "carrier cells," which are ex vivo-infected cells to deliver HSV mutants, and demonstrated the increase in the uptake of virus into tum or and significant reduction in tumor burden and prolonged survival in a model of ovarian cancer (Coukos et al., 1999a) . Furthermore, the efficacy of replication-selecti ve HSV ribonucleotide reductase-deleted mutants can be augmented by expression of a suicide gene such as the endogenous TK or heterogeneous CYP2B1 and subsequent administration of prodrug, ganciclovir or cyclophosphami de (Boviatsis et al., 1994a; Chase et al., 1998) .
Another potential strategy would be to utilize chemotherapeutic agents to modulate the oncolytic effect of HSV mutants. A vast number of chemotherapeut ic agents such as mitomycin C (MMC), cis-platinum II (cis-DDP), doxorubicin (ADR), and methotrexate (MTX) have been studied for the treatment of lung cancer. However, among more than 50 agents tested through the early 1980s, only 5 agents including MMC and cis-DDP dem onstrated significant antitumor activity as a single agent in more than 15% of lung cancer patients (Joss et al., 1984; Gralla and Kris, 1986) . MMC is an alkylating agent and produces intrastrand cross-linking of DNA. It is known to be activated to a cytotoxic interm ediate by bioreduction. cis-DDP is a platinum antitum or compound and forms strong bonds between proteins and nucleic acid. MTX or ADR showed only marginal effects as single agents but they are often included in combination chemotherapy regimens, most containing cis-DDP. MTX is an antifolate. It inhibits dihydrofolate reductase, which is necessary in nucleotide biosynthesis. ADR is an anthracycline and inhibits DNA synthesis by forming a complex between topoisom erase I and II and DNA (Holland et al., 1997) . These four com pounds have been shown to induce apoptosis (Barry et al., 1990; Ohmori et al., 1993; Fukuda and Saijo, 1994; Castaneda and Kinne, 1999) . Chemotherapy has been combined with one or more different modalities (i.e., radiation) to increase the overall patient outcome.
The rationale for combining these chemotherapeut ic agents with an HSV-based oncolytic therapy is as follows: (1) combining conventional chemotherapeut ic agents with HSV-1 mutant may achieve a greater effect than use of either modality alone; (2) a combination of agents with different toxicological profiles may result in increased efficacy without increased overall side effects; (3) the effect of chemotherapy could impact on infected and uninfected cells in the tumor; (4) no overlapping resistance between HSV-1 ICP34.5 mutants and chemotherapeutic agents has been described previously; and (5) the combination may allow the reduction of the HSV-1 mutant dose, thus decreasing the cost of treatment. Here, we examined the efficacy of HSV-1716 in combination with various comm on chemotherapeuti c agents against NSCLC in vitro and in vivo. The interactions betw een the viral and chemotherapeut ic modalities in vitro were analyzed quantitatively by the isobologram method (Carter et al., 1988) . All chemotherapeuti c agents tested augmented the oncolytic effect of HSV-1716 and no antagonism was observed. In addition, the combination of MMC with HSV-1716 produced a synergistic effect in vitro and an additive effect in vivo.
MATERIALS AND METHODS

HSV-1716
HSV-1716 was originally engineered in the laboratory of S.M. Brown (Glasgow, Scotland) from the wild-type (wt) HSV strain 171 , and passaged for use as described (Kucharczuk et al., 1997) . The genome of this virus contains a 759-bp deletion in each copy of the RL1 gene, which encodes ICP34.5 (MacLean et al., 1991) . These deletions remove most of the sequences encoding ICP34.5, resulting in a mutant that fails to make this protein (McKie et al., 1994) . It should be noted that since wt HSV infection can cause encephalitis in hum ans (Whitley, 1996) , we chose to test the antitumor efficacy only of a strain attenuated for neurovirulence.
Cell lines and culture
The human NSCLC cell lines A549, NCI-H460, Calu-1, Calu-3, and NCI-H322 were obtained from the American Type Culture Collection (Rockville, MD). All the cell lines were maintained at 37°C with 5% CO 2 in RPMI 1640 (A549, NCI-H460, and NCI-H322), McCoy's 5A (Calu-1), or Eagle's minimum essential medium (Calu-3), supplemented with 10% heatinactivated fetal bovine serum (FBS), L -glutamine (2 mM), penicillin G (100 U/ml), and streptomycin (100 m g/m l; Life Technologies, Gaithersburg, MD). Calu-3 medium also included nonessential amino acids (0.1 mM; Life Technologies) and sodium pyruvate (1 mM). Cells were harvested during log phase with 0.05% trypsin-EDTA.
Chemotherapeutic agents
Mitomycin C (MMC), doxorubicin (ADR), and methotrexate (MTX) were purchased from Calbiochem (La Jolla, LA). cis-platinum II (cis-DDP) was obtained from Sigma (St. Louis, MO). All stocks of agents at 100 mM were made with phosphate-buffered saline (PBS) and stored at 2 80°C. These agents were diluted with medium without FBS just before use.
Combination of a common chemotherapeutic agent with HSV-1716 in human NSCLC cell lines in vitro
In preliminary experim ents, we examined the chemosensitivity to MMC, cis-DDP, ADR, and MTX, as well as the oncolytic effect of HSV-1716 in the aforementioned hum an NSCLC cell lines (data not shown). In order to observe the interaction between the virus and drugs, we used suboptim al doses of each modality, resulting in less than 50% killing of tumor cells when given a single modality. Cells were plated in 96-well plates at a density of 3000 (A549, NCI-H460, and Calu-1) or 5000 (NCI-H322 and Calu-3) cells per well. Twenty-four hours later, the cells were infected with HSV-1716 at each appropriate multiplicity of infection (MOI) for 1 hr in serum-free medium (50 m l). Subsequently, medium (50 m l) containing 4% heat-inactivated FBS and various concentrations of chemotherapeutic agents was added to the appropriate wells. Cells were then incubated at 37°C in 5% CO 2 . When the cells in the control wells were confluent on day 3 to 5, cell proliferation assays were perform ed with a chromogenic kit (CellTiter 96 aqueous non-radioactive cell proliferation assay; Promega, Madison, WI) that measures viable cell dehydrogenase activity by absorbance at 490 nm, using a microplate reader (EL-800; BioTek Instruments, Winooski, VT). The percentage control was defined as the ratio of the mean absorbance of 18 treatment wells minus the blank to the mean absorbance of 6 untreated matched controls minus the blank. Blank is defined as the mean absorbance of six wells containing medium alone. Each experiment was performed at least twice.
Comparison of cells infected in vitro with HSV-1716 and treated with MMC pre-or postinfection
Three thousand NCI-H460 and A549 cells were plated in 96-well plates. After 24 hr MMC or medium was added for 3 hr in the pretreatment group (A) or posttreatment group (B), respectively. After washing the cells with PBS, HSV-1716 was added for 1 hr under serum-free conditions. Medium containing FBS with MMC (group B) or without MMC (group A) was then added and incubated for 3 hr. Medium on both groups was then replaced with complete medium without MMC. Cell viability was assessed by cell proliferation assay after 48 hr as described above.
One-step growth curves
NCI-H460 cells were plated in six-well plates at a density of 300,000 cells per well in medium (RPMI 1640) with 10% heatinactivated FBS, incubated overnight, and subsequently infected with HSV-1716 at an MOI of 0.1 for 1 hr. In parallel experiments, MMC (0.1 m M) was added for 3 hr before or after infection, or MMC (0.1, 0.3, or 1.0 m M) was added for 48 hr after infection. A sample was harvested 1 hr after exposure to HSV-1716 (0 hr) as well as 6, 19, 24, and 48 hr later by mechanical scraping in their medium. The samples were stored at 2 80°C and titered by plaque assay on baby hamster kidney (BHK) cell monolayers as described previously (Kucharczuk et al., 1997) .
Flow cytometry cell cycle analysis
Cells were cultured in 25-cm 2 flasks and treated with HSV-1716 at an MOI of 10. After 24 hr, cells were harvested with a 0.05% trypsin-EDTA solution. Collected cells were fixed in 80% ethanol at 2 20°C for at least 24 hr, treated with RNase A (500 m g/ml; Sigma) for 30 min at room temperature, stained with propidium iodide (PI, 20 m g/ml), and analyzed with an EPICS XL flow cytometer (Coulter, Hialeah, FL). Data were analyzed by the Cellfit program . Cells displaying less than G 0 (hypodiploid) DNA content were labeled as being located in sub-G 0 , and were considered to exhibit fragmented DNA, i.e., to be apoptotic (Darzynkiewicz et al., 1997) . Results were expressed as means 6 SD.
Cytosol preparations of HSV-infected cells
Cells in exponential growth were infected with HSV-1716 at an MOI of 0.1 or 10. At 6, 19, and 42 hr after infection, cells were then washed twice with PBS and scraped into PBS, using a cell scraper. Cells were then collected by centrifugation at 150 3 g for 10 min at 4°C. The pelleted cells were suspended in a buffer containing 10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 1.5 mM MgCl 2 , and 0.1 mM phenylmethylsul fonyl fluoride (PMSF) and incubated for 10 min at 4°C (Lee et al., 1993) . The cell pellet was disrupted by sonication on ice for 10 sec with a sonicator (VirTis, Gardiner, NY). The homogenate was centrifuged at 105,000 3 g for 30 min at 4°C. Protein concentrations were measured with a protein assay kit (Bio-Rad, Hercules, CA).
Immunoblot analysis
The immunoblot analysis of DT-diaphorase (DTD) expression was performed as previously described (Lee et al., 1993; Molnar-Kim ber et al., 1998) with the following modifications. The cytosolic proteins (1 or 3 m g) were first separated by 12% sodium dodecyl sulfate-polyacryla mide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane at 0.8 mA/cm 2 for 2.5 hr. After transfer, the nitrocellulose was blocked with 4% bovine serum albumin (BSA) in PBS and the protein blots were incubated for 2 hr with a mouse anti-hum an DT-diaphorase monoclonal antibody (KM1015; 2 m g/ml) generously provided by N. Hanai (Kyowa Hakko, Tokyo, Japan). After rinsing, a goat anti-mouse IgG alkaline phosphatase-conjugated antibody (1:7500; Promega) was added for 1 hr. Visualization was performed with brom ochloroindolyl phosphate (BCIP; Amersham , Piscataway, NJ) and nitroblue tetrazolium (NBT; Boehringer Mannheim, Indianapolis, IN).
In vivo xenograft flank model
Six-to 8-week-old CB17 severe combined immunodeficient (SCID) mice (Taconic, Germantown, NY) were housed in isolation units at the Wistar Institute (Philadelphia, PA). NCI-H460 cells were cultured under standard conditions and harvested in log phase with 0.05% trypsin-EDTA solution. After addition of serum -enriched medium, cells were centrifuged at 300 3 g for 5 min at 4°C and resuspended in RPMI 1640. Each injection contained 2 3 10 6 cells in 200 m l of 50% Matrigel (Becton Dickinson Labware, Bedford, MA) in RPMI 1640 medium . After tumors were established (average tumor volume, 163 mm 3 ), mice were divided into 4 groups of 14. The tumors were directly injected with medium or HSV-1716 at a dose of 4 3 10 6 . Mice were given bolus MMC (0.17 mg/kg) or PBS intravenously 24 hr later. The tumor size was measured and volume was calculated at weekly intervals as 0.4 mm 3 length (mm) 3 width (mm) 5 tumor volume (mm 3 ). Tumor growth curves showed mean estimated volume 6 standard error of the mean. After a period of 3-4 weeks, mice were sacrificed and their tumors were weighed. All animal protocols were approved by the Animal Use Committees of the Wistar Institute and the University of Pennsylvania in compliance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health #85-23, revised 1985) .
Statistical analysis
Nonparametric response surface methods (Greco et al., 1995) were employed to analyze the data from a series of drug-virus interaction studies performed in vitro. A three-dim ensional (x, y, and z axes) response surface was defined by dose levels of MMC and HSV-1716 and the resulting outcome (percent control), respectively. As the dose levels of each modality spanned several logs in magnitude, a log base 10 transformation was applied to the data prior to application of nonparametric response surface methods. The nonparam etric response surface was fit with bivariate splines without smoothing, using SAS PROC G3GRID, and plotted with SAS PROC G3D. Isobologram analysis was then performed on the basis of the generated response surface by SAS PROC GCONTOUR. An isobole is a contour plot of constant response (e.g., percent control) associated with a combination of two agents. Isobologram analysis requires the comparison of the observed isobole curve (usually convex or concave) at a particular level of response to the Loewe line of additivity, which is constructed by connecting the two single-agent concentrations that produce that particular level of response. In the concentration ranges employed in this series of experiments, the single-agent concentrations produced responses (percent control) in the range of 80-90%. The reason we demonstrated synergy in the 80-90% range, and not at lower values, was not because the com bination of agents (synergy) was not observed at lower values, but instead was because earlier studies were perform ed to investigate the relevant concentrations at which interactions could be discerned. A selected isobole is then com pared to the Loewe line of additivity (a diagonal northwest-southeast [NW-SE] line). If the isobole is upward concave (arcs beneath the additivity line) synergy is dem onstrated. If the isobole is downward convex (arcs above the additivity line) antagonism is demonstrated. If the isobole closely follows the line, no interaction is demonstrated (Carter et al., 1988) . The interaction index, as proposed by Berenbaum (1981) , was then estimated from the isobologram. Synergy, antagonism, or no interaction (additivity) are dem onstrated if the interaction index is , 1, . 1, or 1, respectively. A mathematical model was then used to assess the statistical significance of the interaction. Piecewise linear models were fit using bivariate splines. The fit of the model without interaction terms was com pared with the fit of a model with interaction terms, by the likelihood ratio test (Mood et al., 1974) , which allow ed statistical significance of the interaction to be determined (p value). The model was constructed using Stata software with the xtreg procedure, that accounted for the correlation among replicates at each MMC-HSV dose level com bination. All in vitro interaction analyses were performed with SAS software (release 6; SAS Institute, Cary, NC) or Stata softw are (release 5; Stata, College Station, TX).
Tumor weights in in vivo experim ents were expressed as means 6 SE. Differences in mean tumor weights in the animal experiments were determined by one-way analysis of variance (ANOVA). Post hoc comparisons among groups were done with the Fisher test (StatView; SAS Institute). Statistical significance was set at p , 0.05.
A linear model with terms for the effects of MMC and HSV-1716 and an interaction term was fit to the in vivo data. The test of synergy between MMC and HSV-1716 was conducted by a one-sided test on the coefficient of the interaction term . In vivo interaction analysis was performed in SPSS (SPSS, Chicago, IL).
RESULTS
Effect of four common chemotherapeutic agents on the oncolytic effect of HSV-1716 as assessed in NCI-H460 in vitro
The effectiveness of the combined treatment of several concentrations of four chemotherapeuti c agents with several MOIs of HSV-1716 was evaluated in the NSCLC cell line NCI-H460 (a large cell carcinoma). Cells were treated with each agent just after infection. It should be noted that the highest dose of the agents used in these in vitro studies was within (cis-DDP, MTX, and ADR) or below (MMC) the peak serum concentrations measured after intravenous administration in human (Boobis et al., 1991; McEvoy, 1999) 
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1716, were displayed in three-dimensiona l (3D) bar charts (Fig.  1A-D) . These figures illustrate the data observed at specific dose combinations of the two agents. Figures 2A and 3A (Fig. 1D) . The isobole based on ED 80 (80% effective dose) values is below the Loewe line of additivity, indicating the presence of synergy in this com bination (Fig. 2B) . The interaction index based on the isobologram is 0.497, which indicates a synergistic effect. The other three agents (cis-DDP, MTX, or ADR) com bined with HSV-1716 resulted in an additive effect. No antagonistic interactions were observed in these studies. UVtreated virus did not show synergism (data not shown).
Combination of MMC with HSV-1716 in five NSCLC cell lines
To determine whether the combination of MMC with HSV-1716 was synergistic in all histopathological types of NSCLC, we tested this combination against four additional NSCLC cell lines (Calu-1 [squam ous cell carcinoma], Calu-3 [adenocarcinom a], NCI-H322 [bronchoalveolar carcinoma], and A549 [undifferentiated lung carcinoma]), representing each of the major histopathological types of non-small cell lung cancer. A summary of interactions resulting from statistical analyses in these five NSCLC lines is shown in Table 1 . A synergistic effect was observed in A549 ( Fig. 3 ; p , 0.00001, interaction index 5 0.655) as well as NCI-H460 (Fig. 2) . The combined therapeutic effect in the other three cell lines appeared additive. No antagonistic effect was observed with the com bination of MMC with HSV-1716 in any cell line tested. We also observed synergism between additional ICP34.5 mutants and MMC in A549 (data not shown).
Comparison of cells infected in vitro with HSV-1716 and treated with MMC pre-or postinfection
To determine whether the timing of MMC administration affected the combined oncolytic effect, H460 and A549 were treated with MMC for 3 hr before or after infection with HSV-1716. Results are shown in Fig. 4 . There were no significant differences in antitumor activity between cells treated with MMC before or after infection with HSV-1716 (p 5 0.11 to 0.97 in NCI-H460, p 5 0.24 to 0.90 in A549; data not shown).
One-step growth curves
One possible mechanism by which the combination of MMC with HSV-1716 could be synergistic is that MMC may augment the ability of HSV-1716 to replicate in NCI-H460 or A549 cells. The effect of MMC on viral replication was measured in one-step growth curve experiments. NCI-H460 cells were infected with HSV-1716 at an MOI of 0.1 for 1 hr and then MMC at 0.1, 1.0, or 3.0 m M was added. At several points, cells were harvested and titered as described previously (Kucharczuk et al., 1997) . As shown in Fig. 5 , pretreatment with 0.1 m M MMC for 3 hr or posttreatment with 0.1 m M MMC for either 3 or 48 hr did not significantly change the burst size in comparison with control (42.1, 57.1, 53.3, and 60.3, respectively). However, the addition of high-dose MMC (1.0 or 3.0 m M) for 48 hr after infection clearly reduced burst size (13.7 and 0.2, respectively). Similar results were observed in A549 (data not shown). Although high-dose MMC may lessen burst size, the synergistic dose of MMC (0.1 m M) neither augmented nor inhibited HSV-1716 replication.
Cell cycle analysis
To examine whether HSV-1716 infection can induce apoptosis and/or affect cell cycle progression, cell cycle analyses by flow cytometry were perform ed. NCI-H460 and A549 cells were infected with HSV-1716 at an MOI of 10 and harvested after 24 hr of incubation. In NCI-H460, apoptosis was observed in 30.4 6 6.0% of cells infected with HSV-1716 compared with 2.5 6 0.3% in noninfected control (Table 2) . HSV-1716 infection of A549 induced only a threefold increase in sub-G 0 fraction, which was significantly less than NCI-H460 (Table 2 , p , 0.0005).
Since the cell cycle phase can influence the sensitivity to MMC (Crooke and Bradner, 1976) , the effect of HSV-1716 infection on progression of cell cycle was determined by fluorescence-activated cell sorting (FACS). In both cell lines tested, HSV-1716 infection did not significantly alter the percentage of cells in the S phase (Table 2) . Taken together, these data suggest that the synergism between HSV-1716 and MMC in NCI-H460 and A549 was due to neither HSV-1716-induced apoptosis nor accumulation in S phase.
DT-diaphora se expression in HSV-infected cells
Another possible mechanism of synergism between MMC and HSV-1716 is that HSV infection may upregulate NAD(P)H:quinone oxidoreductase, which is known as DT-diaphorase (DTD). Cytotoxic activity of MMC is dependent on its intracellular reductive activation to form cross-linked DNA. DTD, which catalyzes the two-electron reduction of quinones and other nitrogen oxides, is known to play a major role in activating MMC. Thus, the level of DTD expression was investigated by immunoblot analysis of protein lysates from four human NSCLC cell lines (NCI-H460, A549, Calu-1, and NCI-H322) that were mock or HSV infected. To maximize the detection of HSV-1716 impact on DTD expression, DTD expression was analyzed in protein lysates isolated from cells infected at an MOI of 10 at both 6 and 19 hr postinfection to observe modulation by early and late HSV genes, respectively. The level of DTD expression was also assessed in cells infected at an MOI of 0.1 for 42 hr to mimic the synergistic conditions in vitro. Each sam ple was analyzed at 1 and 3 m g, which were shown in odd-and even-numbered lanes, respectively, to optimize the ability to detect differences in expression levels. All cell lines expressed the 32-kDa DTD protein band, although at different levels ( Fig. 6A and B, lanes 1 and 2) . As shown in the immunoblot depicted in Fig. 6A , DTD expression was slightly decreased (up to twofold) in HSV-1716-in fected NCI-H460 cells (lanes 5 and 7) and A549 cells (lanes 3, 5, and 7). The decrease in DTD was most evident in NCI-H460 cells infected at an MOI of 10 (NCI-H460; lanes 5 and 7). In NCI-H322 or Calu-1 (Fig. 6B) 
Efficacy of combination of MMC with HSV-1716 in vivo
The in vivo oncolytic efficacy and the interaction of MMC in com bination with HSV-1716 was assessed in a murine xenograft model. Preliminary experiments determ ined that MMC at 0.17 mg/kg or 4 3 10 6 PFU of HSV-1716 yielded tumor sizes of 70 to 80% of untreated control (data not shown). Although these doses may not yield maximum efficacy in this 8) postinfection (p.i.) . Cell lysates were prepared, measured, and 1 or 3 m g was separated by 12% SDS-PAGE as described in Materials and Methods. model, these doses allowed us to investigate the interaction between the two agents. The efficacy of wt HSV combined with chemotherapy was not investigated because this dose of wt HSV would lead to fulminant infection and death of SCID mice (Kucharczuk et al., 1997; Advani et al., 1999) . Established NCI-H460 tumors were treated with vehicle, MMC, HSV-1716, or both MMC and HSV-1716. Tumors were directly injected with either 4 3 10 6 PFU of HSV-1716 or medium. Twenty-four hours later, MMC (0.17 mg/kg) or PBS was administered intravenously. MMC was administered as a single bolus injection to simulate the common procedure of bolus MMC treatment to minimize severe myelosuppressio n (Verweij and Pinedo, 1990) . To examine the effects over time, the tum or volume was measured and calculated at indicated intervals (Fig. 7) . There was a significant decrease in tumor volume between control and all treatment groups (Fig. 7) . The combined treatment group had significantly lower tumor volumes than did each single agenttreated group. Mice were sacrificed and tumors were weighed on day 22. As shown in Fig. 8 , the final mean tumor burden in the vehicle-treated group was 1.406 6 0.079 g. Treatment with HSV-1716 alone reduced tumor burden on average 19.8% to 1.127 6 0.139 g (p 5 0.03 versus control). Treatment with MMC alone reduced tumor burden on average 20.2% to 1.122 6 0.070 g (p 5 0.03 versus control). When both modalities were combined, the mean tum or weight was 0.793 6 0.047 g (p 5 0.01 versus HSV-1716 alone and p 5 0.01 versus MMC alone), significantly less than either individual treatment, yielding only an additive effect. Combined treatment reduced tumor burden on average 43.6% compared with control and there was 29.3% reduction on average over MMC alone and 29.6% on average over HSV-1716 alone. Low-dose MMC, HSV-1716, or com bined therapy did not adversely affect the weight gain of the experimental animals. Thus, the in vivo oncolytic effect of
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FIG. 7. HSV-1716 treatment of subcutaneous hum an lung cancer tumors (NCI-H460) with or without intravenous administration of MMC in SCID mice. HSV-1716 (4 3 10 6 PFU) was injected intratumorally. Mice were given bolus MMC (0.19 mg/kg) intravenously 24 hr later. Tumor size was measured and tum or volume was calculated at regular intervals. Error bars indicate means 6 SE. x axis, time after treatments (days); y axis, calculated mean tumor volume (mm 3 ).
FIG. 8.
Combined efficacy of MMC with HSV-1716 in NCI-H460 in vivo. SCID mice were sacrificed on day 22 and tumors were weighed. Mean tumor burden in the combined treatment group was significantly less than that produced by either individual treatm ent, yielding an additive effect, not a synergistic effect (p 5 0.39). Combined treatment reduced tumor burden 43.6% com pared with the control, which presented a further 29.3% reduction over MMC alone or 29.6% over HSV-1716 alone. Error bars indicate means 6 SE.
com bined MMC and HSV-1716 therapy resulted in suppressed tumor growth in an additive manner.
DISCUSSION
The treatment of human NSCLC remains a formidable problem inasmuch as therapeutic advances have not significantly improved clinical outcom e. The utilization of replication-selective HSV-1 (e.g., HSV-1716) as a therapeutic modality shows much promise. In our laboratory, HSV-1716 has shown efficacy against human NSCLC. However, total eradication of hum an NSCLC tumor nodules (NCI-H460 or A549) in our murine xenograft models has not been achieved by virus alone (Abbas et al., 1998) . Therefore, strategies to improve the efficacy of this form of treatment appear to be important. In efforts to augment the efficacy, we and others have investigated combination therapy with radiation (Advani et al., 1998 (Advani et al., , 1999 Blank et al., 1999; Bouvet et al., 1999) or cytokines, including IL-4 (Andreansky et al., 1998) and IL-12 (Toda et al., 1998a) . Administration of replication-selectiv e HSV-1 mutants utilizing a cell-based delivery system also appears to enhance the uptake of virus into tum or (Coukos et al., 1999a) . Here, we described the com bination studies of chemotherapeut ic agents with HSV-1716 in models of NSCLC by an analytic statistical method. MMC showed a strong synergistic effect in two of five NSCLC cell lines (large cell or undifferentiated carcinoma). In the other three cell lines, the interactions appeared additive. The four chemotherapeut ic agents tested augmented the oncolytic effect of HSV-1716 and no antagonism was observed.
The com bination of MMC with HSV-1716 yielded an additive effect in our murine xenograft model. Since the half-life of MMC is 25-90 min (Verweij and Pinedo, 1990) , one likely interpretation is that the duration of MMC exposure with HSV-1716 infection is important in inducing a synergistic response. In support of this hypothesis, a 3-hr MMC treatment combined with HSV infection yielded only an additive effect whereas a 48-hr MMC treatm ent combined with HSV-1716 infection resulted in synergistic oncolytic activity (Figs. 2 and 4) . These results suggest that synergistic interactions may correlate with a longer duration of MMC contact with tum or cells. Although hum an clinical procedures commonly utilize an intermittent dosing schedule using bolus injections every 4-8 weeks to avoid severe myelosuppressio n (Verweij and Pinedo, 1990) , the use of daily low-dose or continuous injection of MMC instead of a single bolus injection may yield greater efficacy in combination with HSV-1716. This strategy may minimize the potential MMC inhibition of HSV replication. Inhibition of a virus-based oncolytic effect by chemotherapeuti c agents was a concern because these agents are known to block cell proliferation and may also inhibit viral DNA replication. However, our data suggested that the use of chemotherapeutic agents in combination with replication-selectiv e HSV-1716 augmented the efficacy of HSV-based oncolytic therapy. Although we did not measure replication of HSV-1716 in H460 tumor nodules in these combination studies, it is feasible that replication of HSV-1716 may peak within several days. Alternatively, since the ability of H460 to support replication of HSV-1716 was comparable to that of SKOV3 and A2780 in vitro, it is also feasible that replication of HSV-1716 in vivo in H460 cells may be evident as late as 3 weeks postinfectio n, analogous to our findings of the presence of HSV-1716 by immunohistoche mistry in HSV-1716-treate d SKOV3 or A2780 tum ors in murine xenograft models (Coukos et al., 1999a) . HSV-1716-pos itive cells were also observed in melanom a flank tum ors up to 10 days after HSV-1716 administra tion . Regardless of the duration of HSV-1716 replication, it is likely that multiple adm inistrations of HSV-1 ICP34.5 mutants would have improved efficacy in com parison with a single administra tion, as demonstrat ed in murine xenograft models of lung, cervical, and CNS cancer (Advani et al., 1999; A.E. Abbas et al., 1998) .
A combination of adenovirus (Ad)-mediated gene therapy with anti-cancer drugs has also been shown to exhibit a greater effect than either modality alone. Nielsen et al. dem onstrated that paclitaxel had a synergistic or an additive effect when combined with Ad-mediated p53 gene therapy in several cancer models (Nielsen et al., 1997) . Cheon et al. combined an Ad vector, containing the herpes simplex virus thymidine kinase (HSV-TK) gene driven by the osteocalcin promoter, with a low dose of MTX and demonstrated a significant increase in efficacy and prolonged survival in a murine osteosarcom a model (Cheon et al., 1997) . A replication-selecti ve adenovirus, ONYX-015, in combination with 5-fluorouracil (5-FU ) or cis-DDP showed a greater effect than either individual modality and prolonged survival (Heise et al., 1997) . Furthermore, Tong et al. demonstrated that a topoisomerase I inhibitor, topotecan, in com bination with Ad-TK gene therapy yielded a dose-dependent synergistic interaction and that Ad-TK gene therapy enhanced the effect of subsequent chemotherapy in an ovarian cancer model (Tong et al., 1996) . Thus, the com bination of virus-based therapy with chemotherapy for the cancer treatment appears to be promising.
The safety profile of the replication-selectiv e HSV mutants has been investigated in rodents, Aotus monkeys, and currently in phase I hum an clinical trials (Randazzo et al., 1996; Brown et al., 1998; Hunter et al., 1999; Markert et al., 1999) . In several rodent models, the replication of HSV-1716 was restricted to mesothelioma or melanoma tumor nodules (Randazzo et al., 1996; Kucharczuk et al., 1997) . Anti-HSV staining or HSV DNA was not detected by immunohistochemistr y or polymerase chain reaction (PCR), respectively, in surrounding normal tissues, or in distant organs including lung, liver, kidney, brain, and spleen (Kucharczuk et al., 1997) . HSV-1716 replication, in contrast to replication of wt HSV 171 , was also severely restricted in norm al human skin xenografts on the flanks of SCID mice (Randazzo et al., 1996) . Intracerebral inoculation of G207 into the HSV-1-sensitive Aotus monkeys resulted in a rise in serum anti-HSV antibody levels but no observable HSV pathology was detected by histopathological examination or magnetic resonance imaging . There was also no evidence of HSV dissem ination in the G207-injected Aotus monkeys . No limiting toxicities have been observed in the dose escalation phase I clinical trials investigating HSV-1716 or HSV-G207 for the treatment of localized glioblastoma multiforma (Brown et al., 1998; Markert et al., 1999) .
The mechanism(s) of synergistic activity in the combination of MMC with HSV-1716 was postulated to be one or more of the following: (1) MMC augmenting the oncolytic activity of HSV-1716, (2) HSV-1716 enhancing the anti-tumor effect of MMC, or (3) the antitumor effects of the two agents occurring at two distinct points on the same pathway. To investigate potential mechanisms by which MMC could synergize with the oncolytic effect of HSV-1716, it was noted that MMC but not three other chemotherapeutic agents synergized with HSV-1716. Since these four agents have all been shown to induce apoptosis (Barry et al., 1990; Ohmori et al., 1993; Fukuda and Saijo, 1994; Castaneda and Kinne, 1999) , the induction of apoptosis alone was not sufficient to yield a synergistic effect. The distinct responses most likely reflected the different mechanisms of each drug. The second hypothesis was that MMC at the synergistic dose may augment viral replication, analogous to a previous report showing that ionizing radiation of cells infected with an ICP34.5 mutant enhanced its replication (Advani et al., 1998) . However, our data show that although high-dose MMC reduced the replication efficiency of HSV-1716, the synergistic dose of MMC (0.1 m M) neither augmented nor inhibited viral replication (Fig. 5) . Whereas varying the administration schedule of topotecan with Ad-TK gene therapy can modulate the synergistic activity between these two agents in ovarian cancer (Tong et al., 1998) , no significant differences in the effectiveness of the combined therapy of MMC and HSV-1716 infection were observed by varying the time of MMC administration. These data do not support hypothesis 1; that is, the mechanism of the synergism between MMC and HSV-1716 is not caused by MMC augmenting the oncolytic activity of HSV-1716.
A third hypothesis is that HSV-1716 may augment the antitumor activity of MMC. Whereas MMC is a bioreductive alkylating agent (Kennedy et al., 1985) and is know n to induce apoptosis, the mechanisms utilized by wt HSV-1 and mutants to kill infected cells and the mechanism by which cell death proceeds are still a matter of investigation. Galvan and Roizman showed that some wt HSV-infected cells undergo cell death via apoptosis while other cells die a nonapoptotic death, depending on the cell type (Galvan and Roizman, 1998) . It has been proposed that ICP34.5-delete d mutants will induce apoptosis (Chou and Roizm an, 1992; because ICP34.5 protein inhibits premature shutoff of host protein synthesis (Cassady et al., 1998a,b) , and we demonstrated that HSV-1 mutants lacking ICP34.5 can induce cell death via apoptosis in the NSCLC cell line NCI-H460 (Table 2) . However, in the NSCLC line A549 (Table 2) , cell death via nonapoptotic mechanism s appeared dominant, similar to wt HSV (Galvan and Roizman, 1998) . Thus, it is likely that ICP34.5 mutants may induce cell death by either apoptotic or nonapoptotic mechanisms, similar to wt HSV-1 (Galvan and Roizman, 1998) .
The observation that MMC can more effectively kill cells in the S phase of the cell cycle (Crooke and Bradner, 1976) raised the possibility that HSV-1716 infection may influence the rate of cell cycle progression in NSCLC lines. For example, if HSV infection blocked cells from progressing through the S phase of the cell cycle, thereby increasing the percentage of cells in S phase, then the cells may exhibit greater sensitivity to chemotherapeutic agents inhibiting DNA synthesis, such as MMC. However, HSV-1716 infection did not result in the accumulation of NCI-H460 and A549 cells in S phase (Table 2 ) and the mechanism of the MMC and HSV-1716 synergism does not appear to involve HSV-1716 regulation of cell cycle progression in NSCLC cells.
Since the cytotoxic activity of MMC is dependent on its intracellular reductive activation, another possible mechanism of the synergy is the upregulation of the enzymes activating MMC by HSV infection. DT-diaphorase (DTD) catalyzes the twoelectron reduction of MMC to form MMC hydroquinone, which has DNA-alkylating activity (Tomasz et al., 1987; Siegel et al., 1990) . The level of cellular DTD correlates with MMC-induced cytotoxicity in NSCLC cell lines (Malkinson et al., 1992) and the expression level of DTD in immunoblot was directly proportional to its activity (Marin et al., 1997; Mikami et al., 1998) . Furtherm ore, MMC-resistant cell lines showed no or only marginal DTD activity (Begleiter et al., 1989; Siegel et al., 1990; Lee et al., 1993; Pan et al., 19985; Mikami et al., 1996) and introduction of NQO1 gene encoding DTD into DTD-negative St-4 cells rendered them several times more sensitive to MMC (Mikami et al., 1996) . Therefore, we investigated DTD expression in HSV-infected cells by immunoblot assays (Fig. 6) . HSV infection demonstrated slight effects on DTD expression; how ever, we did not observe a distinct association with DTD expression and synergism between MMC and HSV-1716. Although it is possible that HSV may affect other enzymes that play a role in activation of MMC, such as NADPH-cytochrome P-450 reductase (Tomasz and Lipman, 1981; Pan et al., 1984) , xanthine oxidase (Pan et al., 1984) or cytochrome b 5 reductase (Hodnick and Sartorelli, 1993) , which catalyze the one-electron reduction of MMC to its semiquinone radical, these other enzym es did not appear to play a major role in sensitivity of lung cancer cells to MMC (Mikam i et al., 1996; Sakamoto et al., 1997; Cummings et al., 1998) . The interactions between HSV-1 infection and these enzymes have not been described thus far. Since murine cytomegaloviru s suppressed NADPH:cytochrome P450 through virus-induced interferon (Selgrade et al., 1984) , it is feasible that HSV-1 may not increase expression of NADPH:cytocrome P450. In addition, glutathione S-transferase (GST) has been considered to be important in inactivation of MMC . Although bacterial GST has been used in fusion proteins to elucidate function of various HSV genes (Mitchell et al., 1997; Monahan et al., 1998) , the effect of HSV infection on activity of mammalian GST has not been described. If HSV infection inhibits on GST function in NCI-H460 and A549 but not Calu-1, Calu-3, and NCI-H322, it may explain the synergy between HV-1716 and MMC.
As an alternative mechanism, synergism has been shown to occur when two drugs such as cyclosporine A and rapamycin inhibit two distinct points in a given signal transcription pathway, such as T cell activation (Molnar-Kim ber, 1996). Taken together, these data are consistent with the possibility that MMC and HSV-1716 may synergize by affecting distinct points in the cell death pathway used in A549 and NCI-H460. This hypothesis would suggest that A549 and NCI-H460 undergo cell death according to pathways almost identical to those of the other NSCLC lines, but that utilize one or more distinct steps. In summary, we have developed a novel therapeutic strategy for the treatment of NSCLC with an HSV-1 ICP34.5 mutant (HSV-1716) in combination with conventional chemotherapeutic agents. This combination therapy produced an additional therapeutic benefit over either individual modality. In particular, low-dose MMC produced a synergistic effect with HSV-1716 in vitro and an additive effect in vivo. The combination of HSV-based oncolytic therapy and chemotherapy could be used to treat NSCLC, especially to reduce localized tumor burden and tumor-associate d symptoms. Since HSV-1 ICP34.5 mutants have been shown to be efficacious against many non-CNS malignancies such as breast, colon, ovarian, lung cancer, and malignant mesothelioma , combined therapy may augment the effectiveness of HSV-based oncolytic therapy in these as well as additional malignancies.
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